Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up
- 1 February 1978
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences
- Vol. 5 (2) , 175-178
- https://doi.org/10.1017/s0317167100024513
Abstract
SUMMARY: Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.Keywords
This publication has 7 references indexed in Scilit:
- A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosisJournal of the Neurological Sciences, 1976
- INTENSIVE IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSISThe Lancet, 1974
- Evaluation of antithymocyte globulin in acute relapses of multiple sclerosisNeurology, 1974
- Wirkung eines heterologen Antilymphocytenserums auf die experimentelle allergische EncephalomyelitisKlinische Wochenschrift, 1969
- The Effect of Xenogenic Antilymphocyte Serum in Various Stages of Experimental Allergic EncephalomyelitisEuropean Surgical Research, 1969
- ANTILYMPHOCYTE SERUM IN THE LATER STAGES OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITISThe Lancet, 1968
- Further notes on disability evaluation in multiple sclerosis, with scale modificationsNeurology, 1965